Thirty years in healthcare means we've built relationships with the founders, advisors, and intermediaries who think of us early—often before a process starts. That access isn't accidental. It comes from a track record of closing what we say we'll close, structuring deals fairly, and never wasting an operator's time on a process that goes nowhere.
Our investment thesis comes from pattern recognition built over hundreds of healthcare transactions—watching business models emerge, scale, get reimbursed, get squeezed, and adapt. That history gives us a specific point of view on where value is real and where it's temporary: which segments of behavioral health have durable economics, which provider models survive payer consolidation, where post-acute care is heading as Medicare Advantage reshapes incentives. We pursue deals where the fundamentals are sound and the operator has built something that can compound.
And when the fundamentals and the people line up, we don't complicate the rest. We structure deals where the incentives are aligned and the risk is shared fairly—no financial engineering tricks, no terms designed to shift downside onto the operator, no wasted cycles on provisions that exist only to protect one side at the expense of the other. Clean structures that everyone understands, built to make money together.
The best healthcare businesses we've backed had one thing in common: a founder who'd already figured out the hard part. They'd built a care model that delivered outcomes, a referral network that generated volume, a reimbursement strategy that captured value. They didn't need a new strategy. They needed someone who'd seen enough healthcare businesses to know where the leverage was.
We've evaluated hundreds of businesses across provider services, behavioral health, post-acute care, and value-based care. We know which revenue cycle systems break at scale. We know how reimbursement shifts in Medicare Advantage affect margins two years before most operators feel it. We know the difference between a business built on sustainable clinical value and one built on arbitrage that regulators will eventually close.
That pattern recognition lets us identify the two or three things that will meaningfully change a company's trajectory—tighter economics, a key hire, a market expansion the operator already knows is there but hasn't had the capital or bandwidth to pursue—and help make them happen.
